Maxim Group analyst Jason McCarthy has maintained their bullish stance on ZVRA stock, giving a Buy rating today.
Jason McCarthy has given his Buy rating due to a combination of factors including the strong launch of Miplyffa and the strategic financial moves by Zevra Therapeutics. The recent FDA approval of Miplyffa for Niemann-Pick disease type C and its subsequent market introduction have shown promising early adoption, with significant patient enrollment and payor authorizations. This positions the company well for a steep revenue increase as 2025 progresses, especially with the high annual pricing of the drug.
Additionally, the sale of the priority review voucher for $148.3 million has fortified Zevra’s balance sheet, providing non-dilutive funding that secures the company’s financial stability for the foreseeable future. The company’s strategic focus on expanding Miplyffa’s market presence and the ongoing development of other pipeline products, such as Olpruva and KP1077, further support the positive outlook. These factors collectively contribute to McCarthy’s optimistic Buy rating for Zevra Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
ZVRA’s price has also changed slightly for the past six months – from $7.590 to $7.920, which is a 4.35% increase.
Questions or Comments about the article? Write to editor@tipranks.com